Published in Cancer Weekly, July 22nd, 2003
Pretargeting methods involve the separation of antibody-based tumor targeting from the delivery of the therapeutic agent, using bispecific antibodies that bind to both the tumor and the carrier of the therapeutic agent, which is usually a peptide carrying a therapeutic isotope. This allows a rapid uptake of the radiolabeled peptide into the tumor, which results in significantly improved tumor...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.